Clinical trial

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

NCT06081244

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-10-10

PhasePHASE3

Study timeline

Study start (actual)2024-10-10Date precision: day

Registry last updated2026-08-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Interventions

Sacituzumab govitecanDRUG · verified · RxNorm: sacituzumab govitecan

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Women's Cancer Study Group GmbHlead sponsor

Merck Sharp & Dohme LLCcollaborator

Gilead Sciencescollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06081244 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.